Advances in preclinical investigation of prostate cancer gene therapy

Area of Science:

• Oncology
• Gene Therapy
• Medical Virology

Background:

• Recurrent prostate cancer presents significant clinical challenges.
• Adenoviral vector-based gene therapy has emerged as a promising strategy in prostate cancer treatment over the past decade.
• The field is advancing, enabling the translation of preclinical findings into clinical applications.

Purpose of the Study:

• To review and highlight promising adenoviral vector-based gene therapy strategies for recurrent prostate cancer.
• To emphasize the potential of translating preclinical discoveries into clinical practice.
• To discuss current multimodal gene therapy approaches and their early clinical outcomes.

Main Methods:

• Review of recent research and clinical investigations in adenoviral vector-based gene therapy for prostate cancer.
• Focus on specific strategies: prostate-targeted gene expression, oncolytic vectors, reporter gene imaging, and combined treatment modalities.
• Analysis of early-stage clinical trials employing multimodal gene therapy for loco-regional tumor eradication.

Main Results:

• Adenoviral vector-based gene therapy shows potential as an expanded treatment option for prostate cancer.
• Promising strategies include targeted gene expression, oncolytic vectors, and imaging-guided therapy.
• Early clinical investigations using combined, multimodal gene therapy for loco-regional eradication have yielded encouraging results.

Conclusions:

• Adenoviral vector gene therapy is a maturing field with significant potential for recurrent prostate cancer.
• Key strategies are emerging for clinical translation, including targeted and combined treatment modalities.
• Continued research and clinical momentum are crucial to improve patient therapeutic outcomes.